James Watters - Concepedia

Author

James Watters

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

J WATTERS, J Watters, J. Watters, James W Watters, James W. Watters, James Watters, James Wilson Watters, Warner Sarah

225

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Washington University in St. Louis Harvard University United States Military Academy AVEO Oncology (United States)

About

James Watters is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, tumor biology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	358
2	Engineering	3	3	109
3	Biochemistry	3	3	106
4	Health Sciences	2	2	106
5	Biomolecular Engineering	1	1	18

James Watters

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors Ian E. Krop, Tim Demuth, Tina Guthrie, Journal of Clinical Oncology	2012	314
EMT is the dominant program in human colon cancer Andre Loboda, Michael Nebozhyn, James Watters, BMC Medical Genomics	2011	276
MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts N.V. Rajeshkumar, Elizabeth De Oliveira, Niki A. Ottenhof, Clinical Cancer Research	2011	274
Comparative expression pathway analysis of human and canine mammary tumors Paolo Uva, Luigi Aurisicchio, James Watters, BMC Genomics	2009	191
Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter™ Assay System Vladislav A. Malkov, Kyle Serikawa, NOEL BALANTAC, BMC Research Notes	2009	173
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors Andrey Loboda, Michael Nebozhyn, Rich A. Klinghoffer, BMC Medical Genomics	2010	151
Genome-wide discovery of loci influencing chemotherapy cytotoxicity James Watters, Aldi T. Kraja, Melissa A. Meucci, Proceedings of the National Academy of Sciences	2004	144
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Cancer Discovery	2023	103
Kif1C, a kinesin-like motor protein, mediates mouse macrophage resistance to anthrax lethal factor James Watters, Ken Dewar, Jessica A. Lehoczky, Current Biology Macrophage ResistanceProtein FunctionSignal TransductionSignaling PathwayCell Signaling	2001	92
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma Joonil Jung, Joon Sang Lee, Mark A. Dickson, Nature Communications	2016	92

Page 1